Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Torti, Carlo ^a   Lapadula, Guiseppe ^a   Casari, Salvatore ^a   Puoti, Massimo ^a   Nelson, Mark ^b   Quiros Roldan, Eugenia ^a   Bella, Daniele ^c   Pastore, Giuseppe ^d   Ladisa, Nicoletta ^d   Minoli, Lorenzo ^e   Sotgiu, Giovanni ^e   Mazzotta, Francesco ^f   Lo Caputo, Sergio ^f   Di Perri, Giovanni ^e   Filice, Gaetano ^g   Tinelli, Carmine ^e   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c Div Mal Infett   (Italy)

^d POLICLINICO   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^g AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PROTOCOL; DATA BASE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; SUPERINFECTION; TREATMENT OUTCOME; COHORT ANALYSIS; DRUG EFFECT; ENZYMOLOGY; ITALY; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TOXIC HEPATITIS;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; LIVER; LIVER FUNCTION TESTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 27344441697     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-58     Document Type: Article

References (16)

1. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998, 12:1256.
2. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
3. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
4. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15:1261-1268.
5. Monforte AA, Bugarini R, Pezzotti P, De LA, Antinori A, Mussini C, Vigevani GM, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De SC, Pizzigallo E, Perrella O, Moroni M: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001, 28:114-123.
6. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K: Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002, 16:737-745.
7. Dietrich DT, Becker SL, Fusco JS, Balu RB, Most BM, Stern J, Lanes S, Fusco GP: Low incidence of grade III/IV hepatotoxicity in first HAART: observations from 1100 patients followed for 1 year. XIV International AIDS Conference (Barcelona) TuPeB4543 2002.
8. Justice AC, Wagner JH, Fusco GP, Dieterich DT, Becker SL, McGinnis KA, Conigliaro J, Bonomo R, Rodriguez-Barradas M: HIV survival: liver function tests independently predict survival. XIV International AIDS Conference (Barcelona) MoOrB1058 2002.
9. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31.
10. Aceti A, Pasquazzi C, Zechini B, De Bac C: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002, 29:41-48.
11. Dieterich DT, Robinson PA, Love J, Stern JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38 Suppl 2:S80-S89.
12. Sherman KE, Shire NJ, Cernhous P, Rouster SD, Da Silva B, Brun S: Evaluation of HCV RNA and liver injury in HCV/HIV coin-fected patients initiating lopinavir/r or nelfinavir-based therapy. 11th CROI (San Francisco,CA) 2004.
13. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18:2277-2284.
14. Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S, Danise A, Moioli MC, Angeli E, Bongiovanni M, Hasson H, Duca P, Cargnel A: Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004, 5:334-343.
15. Chirlin S, Loufty MR, Raboud J, Saskin R, Fletcher D, Rachlis A, Kovacs C, Walmsley S, Phillips E: Exposure to lopinavir/r is a risk factor for grade 3/4 elevations of ALT in HIV and hepatitis B and/or hepatitis C coinfected patients. Annual conference of the Canadian Association for HIV Research (Montreal) 217 2004.
16. Group AIDSCT: Table of grading severity of adult adverse experiences. Rockville, MD: US Division of AIDS, National Institute of Allergy and Infectious Disease. 1996.